EP3470059A1 — Ophthalmic suspension composition
Assigned to Bausch and Lomb Inc · Expires 2019-04-17 · 7y expired
What this patent protects
A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D v90 < 5 µm and D v50 < 1 µm. The suspension may be admin…
USPTO Abstract
A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D v90 < 5 µm and D v50 < 1 µm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.
Drugs covered by this patent
- Lotemax (LOTEPREDNOL ETABONATE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.